Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EMUC 2018: POTOMAC & ALBAN trials

Dr. Evanguelos Xylinas, urologist at Cochin Hospital, Paris Descartes University (France), is chief editor of the bladder cancer section of the UROONCO educational platform and talks about the POTOMAC trial (durvalumab plus BCG vs. BCG) and the ALBAN trial (atezolizumab plus BCG vs. BCG).

Related items